Neurim v. Mylan-- the Illiad was shorter By Frantzeska Papadopoulou on Tuesday, February 01, 2022 Circadin divisional Frantzeska Papadopoulou lay patient mylan Neurim plausibility +
The Swedish Patent and Market Court of Appeal applies "Abraxis" in rejecting Supplementary Protection Certificate By Frantzeska Papadopoulou on Wednesday, February 26, 2020 Abraxis Frantzeska Papadopoulou Market authorization MIT Neurim SPC Supplementary Protection Certificate Yissum +
BREAKING: CJEU delivers another blow to SPC owners in Abraxis Article 3(d) (or 1(b)) battle By Annsley Merelle Ward on Thursday, March 21, 2019 Abraxis AmeriKat Article 1(b) Article 3(d) CJEU MIT Neurim pharmaceutical industry SPC SPC regulation Yissum +
The Opinion of the Advocate General in the case C-443/17 (Abraxis case). A lost case for second medical indication SPCs? By Frantzeska Papadopoulou on Sunday, December 23, 2018 Abraxis Neurim second medical indication SPC +
Introducing the AdvoKat: Does Neurim represent an important development in SPC jurisprudence? By Annsley Merelle Ward on Friday, July 20, 2012 AdvoKat CJEU ruling Court of Justice of the European Union Neurim Second medical use SPCs +